Credit: Shutterstock/Dragana Gordic
Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) primarily focusing on coeliac disease. Takeda will secure exclusive worldwide rights to use a set of Innate antibodies to create, manufacture and commercialise the ADCs. In addition to milestone-based payments, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.
India’s Cipla signs licence deal with Novartis for diabetes drug Galvus
India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. Galvus brand products are mainly used in the treatment of patients with type 2 diabetes.
GSK signs licence deal with Scynexis for fungal infection treatment
GSK has signed an exclusive licence agreement with Scynexis to commercialise and further develop Brexafemme (ibrexafungerp tablets) to treat fungal infection. GSK will obtain the rights to commercialise the new oral glucan synthase inhibitor for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC).
BioNTech and DualityBio team up to develop ADC therapeutics for cancer
BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. As part of the new deals, BioNTech will have commercial rights to the ADCs worldwide, excluding mainland China, the Hong Kong special administrative region and the Macau special administrative region.